Therapeutic exploitation of oncolytic viruses in pediatric oncology

Drugs of the Future

Volumn 35, Issue 12, 2010, Pages 1015-1027

  Lacroix, J ^a,b   Witt, O ^a,b   Schlehofer, J R ^a   Rommelaere, J ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUCYTOSINE; FLUOROURACIL; JX 594; NTX 010; ONCOLYTIC ADENO ASSOCIATED VIRUS; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC MYXOMA VIRUS; ONCOLYTIC PARVOVIRUS; ONCOLYTIC SEMLIKI FOREST VIRUS; ONCOLYTIC SENECA VALLEY VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; RAPAMYCIN; REOLYSIN; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADENO ASSOCIATED VIRUS; BURKITT LYMPHOMA; CANCER GRADING; CANCER IMMUNIZATION; CHILD HEALTH; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; EVENT FREE SURVIVAL; EWING SARCOMA; GENE DIRECTED ENZYME PRODRUG THERAPY; GLIOBLASTOMA; GLIOMA; HEPATOBLASTOMA; HERPES SIMPLEX VIRUS; HUMAN; IMMUNE RESPONSE; LYMPHOMA; MEDULLOBLASTOMA; MYXOMA VIRUS; NEPHROBLASTOMA; NEUROBLASTOMA; NEWCASTLE DISEASE PARAMYXOVIRUS; NONHODGKIN LYMPHOMA; NONHUMAN; ONCOLOGY; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PHASE 1 CLINICAL TRIAL (TOPIC); RETINOBLASTOMA; REVIEW; RHABDOID TUMOR; RHABDOMYOSARCOMA; SARCOMA; SEMLIKI FOREST ALPHAVIRUS; SIGNAL TRANSDUCTION; SURVIVAL RATE; TREATMENT RESPONSE; VESICULAR STOMATITIS VIRUS; VIRUS ATTENUATION; VIRUS ENTRY; VIRUS MUTANT; VIRUS REPLICATION;

EID: 79956201676     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2010.035.012.1521419     Document Type: Review

References (96)

1. Kurmasheva, R.T., Houghton, P.J. Pediatric oncology. Curr Opin Chem Biol 2007, 11(4): 424-32.
2. Gatta, G., Zigon, G., Capocaccia, R. et al. Survival of European children and young adults with cancer diagnosed 1995-2002. Eur J Cancer 2009, 45(6): 992-1005.
3. Liu, T.C., Kirn, D. Gene therapy progress and prospects cancer: Oncolytic viruses. Gene Ther 2008, 15(12): 877-84.
4. Kumar, S., Gao, L., Yeagy, B., Reid, T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008, 10(4): 371-9.
5. Li, Q.X., Yu, D.H., Liu, G., Ke, N., McKelvy, J., Wong-Staal, F. Selective anti-cancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ 2008, 15(8): 1197-210.
6. Li, Q.X., Liu, G., Wong-Staal, F. Oncolytic virotherapy as a personalized cancer vaccine. Int J Cancer 2008, 123(3): 493-9.
7. Friedman, G.K., Pressey, J.G., Reddy, A.T., Markert, J.M., Gillespie, G.Y. Herpes simplex virus oncolytic therapy for pediatric malignancies. Mol Ther 2009, 17(7): 1125-35.
8. Hammill, A.M., Conner, J., Cripe, T.P. Oncolytic virotherapy reaches adolescence. Pediatr Blood Cancer 2010, Epub ahead of print.
9. Freeman, A.I., Zakay-Rones, Z., Gomori, J.M. et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006, 13(1): 221-8.
10. Everts, B., van der Poel, H.G. Replication-selective oncolytic viruses in the treatment of cancer. Cancer Gene Ther 2005, 12(2): 141-61.
11. Comins, C., Heinemann, L., Harrington, K., Melcher, A., de Bono, J., Pandha, H. Reovirus: Viral therapy for cancer 'as nature intended'. Clin Oncol (R Coll Radiol) 2008, 20(7): 548-54.
12. Ungerechts, G., Springfeld, C., Frenzke, M.E. et al. An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol Ther 2007, 15(11): 1991-7.
13. Lun, X.Q., Zhou, H., Alain, T. et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007, 67(18): 8818-27.
14. Lun, X., Alain, T., Zemp, F.J. et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin. Cancer Res 2010, 70(2): 598-608.
15. Alain, T., Lun, X., Martineau, Y. et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A 2010, 107(4): 1576-81.
16. Cody, J.J., Douglas, J.T. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009, 16(6): 473-88.
17. Cattaneo, R., Miest, T., Shashkova, E.V., Barry, M.A. Reprogrammed viruses as cancer therapeutics: Targeted, armed and shielded. Nat Rev Microbiol 2008, 6(7): 529-40.
18. Springfeld, C., von Messling, V., Frenzke, M., Ungerechts, G., Buchholz, C.J., Cattaneo, R. Oncolytic efficacy and enhanced safety of measles virus activated by tumor-secreted matrix metalloproteinases. Cancer Res 2006, 66(15): 7694-700.
19. Ungerechts, G., Springfeld, C., Frenzke, M.E. et al. Lymphoma chemovirotherapy: CD20-targeted and convertase-armed measles virus can synergize with fludarabine. Cancer Res 2007, 67(22): 10939-47.
20. Mahller, Y.Y., Williams, J.P., Baird, W.H. et al. Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 2009, 4(1): e4235.
21. Nemunaitis, J., Tong, A.W., Nemunaitis, M. et al. A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ther 2010, 18(2): 429-34.
22. Rommelaere, J., Geletneky, K., Angelova, A.L. et al. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev 2010, Epub ahead of print.
23. Kaur, B., Cripe, T.P., Chiocca, E.A. "Buy one get one free": Armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009, 9(5): 341-55.
24. Prestwich, R.J., Harrington, K.J., Pandha, H.S., Vile, R.G., Melcher, A.A., Errington, F. Oncolytic viruses: A novel form of immunotherapy. Expert Rev Anticancer Ther 2008, 8(10): 1581-8.
25. Cerullo, V., Pesonen, S., Diaconu, I. et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010, Epub ahead of print.
26. Hu, J.C., Coffin, R.S., Davis, C.J. et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006, 12(22): 6737-47.
27. Merrick, A.E., Ilett, E.J., Melcher, A.A. JX-594, a targeted oncolytic poxvirus for the treatment of cancer. Curr Opin Investig Drugs 2009, 10(12): 1372-82.
28. Bridle, B.W., Hanson, S., Lichty, B.D. Combining oncolytic virotherapy and tumour vaccination. Cytokine Growth Factor Rev 2010, Epub ahead of print.
29. Alvarez-Breckenridge, C., Kaur, B., Chiocca, E.A. Pharmacologic and chemical adjuvants in tumor virotherapy. Chem Rev 2009, 109(7): 3125-40.
30. Geletneky, K., Hartkopf, A.D., Krempien, R., Rommelaere, J., Schlehofer, J.R. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus h-1 infection. J Biomed Biotechnol 2010, 2010: 350748.
31. Opyrchal, M., Aderca, I., Galanis, E. Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas. Methods Mol Biol 2009, 542: 705-17.
32. Morton, C.L., Houghton, P.J., Kolb, E.A. et al. Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer 2010, 55(2): 295-303.
33. Lichty, B.D., Stojdl, D.F., Taylor, R.A. et al. Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy. Hum Gene Ther 2004, 15(9): 821-31.
34. Kim, M., Madlambayan, G.J., Rahman, M.M. et al. Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells. Leukemia 2009, 23(12): 2313-7.
35. Xie, M., Niu, J.H., Chang, Y. et al. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 2009, 14(9): 1086-94.
36. Small, D. Targeting FLT3 for the treatment of leukemia. Semin Hematol 2008, 45(3, Suppl. 2): S17-21.
37. Rahman, M.M., Madlambayan, G.J., Cogle, C.R., McFadden, G. Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus. Cytokine Growth Factor Rev 2010, Epub ahead of print.
38. Bluming, A.Z., Ziegler, J.L. Regression of Burkitt's lymphoma in association with measles infection. Lancet 1971, 2(7715): 105-6.
39. Esfandyari, T., Tefferi, A., Szmidt, A. et al. Transcription factors downstream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus. Mol Oncol 2009, 3(5-6): 464-8.
40. Shmulevitz, M., Pan, L.Z., Garant, K., Pan, D., Lee, P.W. Oncogenic Ras promotes reovirus spread by suppressing IFN-{beta} production through negative regulation of RIG-I signaling. Cancer Res 2010, Epub ahead of print.
41. Alain, T., Hirasawa, K., Pon, K.J. et al. Reovirus therapy of lymphoid malignancies. Blood 2002, 100(12): 4146-53.
42. Angelova, A.L., Aprahamian, M., Balboni, G. et al. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther 2009, 17(7): 1164-72.
43. Zulkifli, M.M., Ibrahim, R., Ali, A.M. et al. Newcastle diseases virus strain V4UPM displayed oncolytic ability against experimental human malignant glioma. Neurol Res 2009, 31(1): 3-10.
44. Wilcox, M.E., Yang, W., Senger, D. et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001, 93(12): 903-12.
45. Yang, W.Q., Lun, X., Palmer, C.A. et al. Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: Racine and nonhuman primates. Clin Cancer Res 2004, 10(24): 8561-76.
46. Heikkila, J.E., Vaha-Koskela, M.J., Ruotsalainen, J.J. et al. Intravenously administered alphavirus vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PLoS One 2010, 5(1): e8603.
47. Geletneky, K., Kiprianova, I., Ayache, A. et al. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol 2010, Epub ahead of print.
48. Grandi, P., Peruzzi, P., Reinhart, B., Cohen, J.B., Chiocca, E.A., Glorioso, J.C. Design and application of oncolytic HSV vectors for glioblastoma therapy. Expert Rev Neurother 2009, 9(4): 505-17.
49. Phuong, L.K., Allen, C., Peng, K.W. et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res 2003, 63(10): 2462-9.
50. Kyritsis, A.P., Sioka, C., Rao, J.S. Viruses, gene therapy and stem cells for the treatment of human glioma. Cancer Gene Ther 2009, 16(10): 741-52.
51. Immonen, A., Vapalahti, M., Tyynela, K. et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: A randomised, controlled study. Mol Ther 2004, 10(5): 967-72.
52. Packer, R.J., Rood, B.R., MacDonald, T.J. Medulloblastoma: Present concepts of stratification into risk groups. Pediatr Neurosurg 2003, 39(2): 60-7.
53. Radbill, A.E., Reddy, A.T., Markert, J.M. et al. Effects of G207, a conditionally replication-competent oncolytic herpes simplex virus, on the developing mammalian brain. J Neurovirol 2007, 13(2): 118-29.
54. Yang, W.Q., Senger, D., Muzik, H. et al. Reovirus prolongs survival and reduces the frequency of spinal and leptomeningeal metastases from medulloblastoma. Cancer Res 2003, 63(12): 3162-72.
55. Studebaker, A.W., Kreofsky, C.R., Pierson, C.R., Russell, S.J., Galanis, E., Raffel, C. Treatment of medulloblastoma with a modified measles virus. Neuro Oncol 2010, Epub ahead of print.
56. Lasner, T.M., Kesari, S., Brown, S.M., Lee, V.M., Fraser, N.W., Trojanowski, J.Q. Therapy of a murine model of pediatric brain tumors using a herpes simplex virus type-1 ICP34.5 mutant and demonstration of viral replication within the CNS. J Neuropathol Exp Neurol 1996, 55(12): 1259-69.
57. Stolarek, R., Gomez-Manzano, C., Jiang, H., Suttle, G., Lemoine, M.G., Fueyo, J. Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma. Cancer Gene Ther 2004, 11(11): 713-20.
58. Strong, J.E., Coffey, M.C., Tang, D., Sabinin, P., Lee, P.W. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17(12): 3351-62.
59. Reddy, P.S., Burroughs, K.D., Hales, L.M. et al. Seneca Valley virus, a systemically deliverable oncolytic picornavirus, and the treatment of neuroendocrine cancers. J Natl Cancer Inst 2007, 99(21): 1623-33.
60. Lacroix, J., Leuchs, B., Li, J. et al. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer 2010, 127(5): 1230-9.
61. Wagner, L.M., Guichard, S.M., Burger, R.A. et al. Efficacy and toxicity of a virus-directed enzyme prodrug therapy purging method: Preclinical assessment and application to bone marrow samples from neuroblastoma patients. Cancer Res 2002, 62(17): 5001-7.
62. Toyoda, H., Yin, J., Mueller, S., Wimmer, E., Cello, J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 2007, 67(6): 2857-64.
63. Parikh, N.S., Currier, M.A., Mahller, Y.Y. et al. Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus type 5 for the treatment of high-risk neuroblastomas in preclinical models. Pediatr Blood Cancer 2005, 44(5): 469-78.
64. Mahller, Y.Y., Vaikunth, S.S., Ripberger, M.C. et al. Tissue inhibitor of metalloproteinase- 3 via oncolytic herpesvirus inhibits tumor growth and vascular progenitors. Cancer Res 2008, 68(4): 1170-9.
65. Farrell, C.J., Zaupa, C., Barnard, Z. et al. Combination immunotherapy for tumors via sequential intratumoral injections of oncolytic herpes simplex virus 1 and immature dendritic cells. Clin Cancer Res 2008, 14(23): 7711-6.
66. Davidoff, A.M., Nathwani, A.C., Spurbeck, W.W., Ng, C.Y., Zhou, J., Vanin, E.F. rAAV-mediated long-term liver-generated expression of an angiogenesis inhibitor can restrict renal tumor growth in mice. Cancer Res 2002, 62(11): 3077-83.
67. Smith, M.A., Morton, C.L., Phelps, D., Girtman, K., Neale, G., Houghton, P.J. SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer 2008, 50(3): 703-6.
68. Kuroda, T., Rabkin, S.D., Martuza, R.L. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res 2006, 66(20): 10127-35.
69. Ottaviani, G., Jaffe, N. The epidemiology of osteosarcoma. Cancer Treat Res 2009, 152: 3-13.
70. Toolan, H.W., Saunders, E.L., Southcam, CM.,. Moore, A.E., Levin, A.G. H-1 virus viremia in the human. Proc Soc Exp Biol Med 1965, 119: 711-5.
71. Ketola, A., Hinkkanen, A., Yongabi, F. et al. Oncolytic Semliki forest virus vector as a novel candidate against unresectable osteosarcoma. Cancer Res 2008, 68(20): 8342-50.
72. Witlox, M.A., Lamfers, M.L., Wuisman, P.I., Curiel, D.T., Siegal, G.P. Evolving gene therapy approaches for osteosarcoma using viral vectors: Review. Bone 2007, 40(4): 797-812.
73. Graat, H.C., van Beusechem, V.W., Schagen, F.H. et al. Intravenous administration of the conditionally replicative adenovirus Ad5-Delta24RGD induces regression of osteosarcoma lung metastases. Mol Cancer 2008, 7: 9.
74. Dmitriev, I., Krasnykh, V., Miller, C.R. et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998, 72(12): 9706-13.
75. Witlox, A.M., van Beusechem, V.W., Molenaar, B. et al. Conditionally replicative adenovirus with tropism expanded towards integrins inhibits osteosarcoma tumor growth in vitro and in vivo. Clin Cancer Res 2004, 10(1, Pt. 1): 61-7.
76. Li, X., Jung, C., Liu, Y.H. et al. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis. J Gene Med 2006, 8(6): 679-89.
77. Bharatan, N.S., Currier, M.A., Cripe, T.P. Differential susceptibility of pediatric sarcoma cells to oncolysis by conditionally replication-competent herpes simplex viruses. J Pediatr Hematol Oncol 2002, 24(6): 447-53.
78. Rice, A.M., Currier, M.A., Adams, L.C. et al. Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis. J Pediatr Hematol Oncol 2002, 24(7): 527-33.
79. Wolden, S.L., Alektiar, K.M. Sarcomas across the age spectrum. Semin Radiat Oncol 2010, 20(1): 45-51.
80. Cinatl, J. Jr., Cinatl, J., Michaelis, M. et al. Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Res 2003, 63(7): 1508-14.
81. Currier, M.A., Adams, L.C., Mahller, Y.Y., Cripe, T.P. Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses. Cancer Gene Ther 2005, 12(4): 407-16.
82. Currier, M.A., Gillespie, R.A., Sawtell, N.M. et al. Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide. Mol Ther 2008, 16(5): 879-85.
83. Ji, X., Zhang, J., Cheng, L. et al. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 2009, 89(2): 193-9.
84. Wadhwa, L., Hurwitz, M.Y., Chevez-Barrios, P., Hurwitz, R.L. Treatment of invasive retinoblastoma in a murine model using an oncolytic picornavirus. Cancer Res 2007, 67(22): 10653-6.
85. Rosen, J.M., Jordan, C.T. The increasing complexity of the cancer stem cell paradigm. Science 2009, 324(5935): 1670-3.
86. Cripe, T.P., Wang, P.Y., Marcato, P., Mahller, Y.Y., Lee, P.W. Targeting cancer-initiating cells with oncolytic viruses. Mol Ther 2009, 17(10): 1677-82.
87. Csatary, L.K., Gosztonyi, G., Szeberenyi, J. et al. MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 2004, 67(1-2): 83-93.
88. Wagner, S., Csatary, C.M., Gosztonyi, G. et al. Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 2006, 114(10): 731-43.
89. Harrow, S., Papanastassiou, V., Harland, J. et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: Safety data and long-term survival. Gene Ther 2004, 11(22): 1648-58.
90. Mace, A.T., Ganly, I., Soutar, D.S., Brown, S.M. Potential for efficacy of the oncolytic herpes simplex virus 1716 in patients with oral squamous cell carcinoma. Head Neck 2008, 30(8): 1045-51.
91. MacKie, R.M., Stewart, B., Brown, S.M. Intralesional injection of herpes simplex virus 1716 in metastatic melanoma. Lancet 2001, 357(9255): 525-6.
92. Fukazawa, T., Matsuoka, J., Yamatsuji, T., Maeda, Y., Durbin, M.L., Naomoto, Y. Adenovirus-mediated cancer gene therapy and virotherapy. Int J Mol Med 2010, 25(1): 3-10.
93. Wu, Y., Lun, X., Zhou, H. et al. Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. Clin Cancer Res 2008, 14(4): 1218-27.
94. Allen, C., Paraskevakou, G., Liu, C. et al. Oncolytic measles virus strains in the treatment of gliomas. Expert Opin Biol Ther 2008, 8(2): 213-20.
95. Herrero y Calle, M., Cornelis, J.J., Herold-Mende, C., Rommelaere, J., Schlehofer, J.R., Geletneky, K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer 2004, 109(1): 76-84.
96. Graat, H.C., Witlox, M.A., Schagen, F.H. et al. Different susceptibility of osteosarcoma cell lines and primary cells to treatment with oncolytic adenovirus and doxorubicin or cisplatin. Br J Cancer 2006, 94(12): 1837-44.